Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic drugs, has announced the completion of a Series A financing round worth RMB 100 million (USD 14.5 million). The investment was led by Jiangsu Tech Industry Investment Co., Ltd.
Company Background and Services
Founded in 2019, Bioworkshops offers a comprehensive range of services in the biopharmaceutical sector, including process development, raw materials cGMP manufacturing, and sterile formulation filling. The company’s capabilities are underscored by its 13,000L stock solution production capacity, which positions it as a significant player in the biologic drugs market.
Implications of Financing for Bioworkshops
The successful Series A financing round will enable Bioworkshops to further expand its operations and enhance its service offerings in the biologic drugs space. This funding is expected to support the company’s growth, allowing it to meet the increasing demand for high-quality biologic drug development and manufacturing services.-Fineline Info & Tech
